NCT01400516View on ClinicalTrials.gov

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

July 30, 2015

Study Completion Date

July 28, 2016

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Teriparatide

20 μg, subcutaneous injection, 1 injection per day

DRUG

calcium citrate

1000 mg of calcium citrate

DRUG

Vitamin D

800 IU of Vitamin D

DRUG

TNF antagonist

TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

01605

University of Massachusetts Medical School, Worcester

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT01400516 - Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial | Biotech Hunter | Biotech Hunter